MARKET

VRTX

VRTX

Vertex Pharmaceuticals Inc
NASDAQ
445.87
+0.66
+0.15%
After Hours: 445.87 0 0.00% 18:27 05/20 EDT
OPEN
444.72
PREV CLOSE
445.21
HIGH
447.85
LOW
442.99
VOLUME
742.23K
TURNOVER
0
52 WEEK HIGH
448.40
52 WEEK LOW
320.01
MARKET CAP
115.06B
P/E (TTM)
28.92
1D
5D
1M
3M
1Y
5Y
Vertex Pharmaceuticals on Track for Record High Close -- Data Talk
Dow Jones · 14h ago
PTC Therapeutics rallies 18% on EU authorization update for Translarna
PTC Therapeutics rallies 18% on EU authorization update for Translarna. The company announced the European Commission is allowing its Duchenne muscular dystrophy therapy to remain on the market in Europe. PTC's stock rallied 18% early Monday after the announcement.
Seeking Alpha · 17h ago
Weekly Report: what happened at VRTX last week (0513-0517)?
Weekly Report · 21h ago
Novo Nordisk, J&J lead R&D rankings in big pharma: report
Healthcare Novo Nordisk, J&J lead R&D rankings in big pharma: report in 2024 Innovation Index. Danish drugmaker has dethrone Pfizer from its two-year leadership in the index. Johnson & Johnson topped the 2024 Invention Index.
Seeking Alpha · 2d ago
VERTEX PHARMACEUTICALS INC: ADDITION OF SCHNEIDER BRINGS VERTEX'S BOARD OF DIRECTORS TO 11 MEMBERS
Reuters · 5d ago
Pfizer, Freeport-McMoRan, Vertex Pharmaceuticals And A Major Tech Stock On CNBC's 'Final Trades'
Benzinga · 5d ago
Tracking Tweedy Browne Portfolio - Q1 2024 Update
Seeking Alpha · 5d ago
Jennifer Schneider Elected to Vertex Board of Directors
Jennifer Schneider has more than two decades of experience in the health care industry. She co-founded and serves as Chief Executive Officer of Homeward Health. Dr. Schneider brings Vertex’s board of directors to 11. Vertex is a global biotechnology company that develops medicines for people with serious diseases.
Barchart · 5d ago
More
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

Webull offers Vertex Pharmaceuticals Incorporated stock information, including NASDAQ: VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.